权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Food-specific antibodies and urologic chronic pelvic pain syndrome.

食物特异性抗体和泌尿系统慢性盆腔疼痛综合征。

基本信息

批准号：
10452193
负责人：
Siobhan Sutcliffe
金额：
$ 25.3万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-15 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10452193
关键词：
Adopted Affect American Antibodies Antibody Response Asthma Biological Biological Markers Blinded Case Study Cattle Cell Degranulation Chronic Chronic Prostatitis Citrus Fruit Clinical Management Clinical Trials Crohn&apos s disease Cross-Over Studies Data Diet Employment Evaluation Exclusion Failure Feeling suicidal Flare Food Frequencies Functional disorder Goals Healthcare Systems Histamine Release Home Hour Immunoglobulin G Individual Interstitial Cystitis Intervention Irritable Bowel Syndrome Mental Health Migraine Milk Operative Surgical Procedures Pain Participant Pathology Patient Self-Report Patients Pattern Pelvic Pain Pharmacology Phase Pilot Projects Placebo Effect Plasma Predisposition Public Health Randomized Controlled Trials Reporting Research Research Personnel Sampling Sexual Health Suggestion Surveys Symptoms Syndrome Testing Text Time Work arm bladder pain candidate identification chronic pelvic pain clinical phenotype cost dietary effective therapy experience improved interdisciplinary approach mast cell novel therapeutic intervention novel therapeutics phenotypic data physical conditioning pilot trial reduce symptoms side effect success tool urinary urologic chronic pelvic pain syndrome

项目摘要

(PLEASE KEEP IN WORD, DO NOT PDF) Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. Interstitial cystitis/bladder pain syndrome (IC/BPS) and chronic prostatitis/chronic pelvic pain syndrome (CP/ CPPS), are common, costly, and debilitating syndromes characterized by persistent bladder and/or pelvic pain, and urinary symptoms, such as urgency and frequency. The cause of these conditions, together referred to as urologic chronic pelvic pain syndrome (UCPPS), is unknown and their pathophysiology is poorly understood,making treatment challenging. Although several therapies have been proposed for UCPPS, none has been found to work consistently in all patients and each is either invasive or prone to significant side effects. Therefore, new therapeutic approaches are clearly needed. One such promising, but understudied, approach is dietary exclusion. This approach is supported by findings from one small single-arm trial (n=10), two case reports, our recent Multidisciplinary Approach to the Study of Chronic Pelvic Pain 1 (MAPP-1) Research Network case-crossover study, and several patient surveys indicating that a large proportion of patients believe that diet triggers their flares. However, as patient-reported triggers are numerous and wide-ranging (up to 144 candidates), identification of one common diet suitable for all patients has proven challenging. Elimination diets are also difficult to implement and test because of the large number of possible food triggers that need to be eliminated in the “elimination” phase, the large number that need to be re-introduced in the “re-introduction” phase, and the challenges of blinding elimination diets. Therefore, tools to personalize these diets are urgently needed. In pilot trials of patients with migraines, Crohn’s disease, irritable bowel syndrome, and asthma, researchers have observed significant symptom reductions following exclusion diets informed by food-specific IgG antibody concentrations. This approach is promising because it reduces the time, complexity, and burden of dietary exclusion, while simultaneously increasing its chance of success and potential for rigorous blinded evaluation. Food-specific IgG antibodies are also plausible candidates to inform UCPPS therapy because they act by biologic mechanisms implicated in UCPPS pathology (e.g. mast cell degranulation and histamine release) and in a “delayed” time frame (hours to days) consistent with patient-reported food trigger experiences. However, before we can initiate a randomized controlled trial (RCT) of food-specific IgG antibody-informed exclusion diets for UCPPS, additional empirical evidence is necessary to support this approach. For many conditions for which biomarker-informed exclusion diets have shown preliminary efficacy, researchers first demonstrated a greater likelihood of having food-specific IgG antibodies in patients than controls. We have also generated promising pilot data in a small sample of 10 UCPPS patients (100% had food-specific IgG antibodies compared to 15-33% of historical controls). In this R01, we plan to build on these promising findings by formally testing whether UCPPS patients have greater food sensitivity than controls, using existing plasma samples and clinical phenotyping data from 100 cases and 100 controls from the MAPP-1 study.

（请保存文字，不要使用pdf格式）